MWI Health

MWI Health in Sioux Falls, South Dakota offers Spravato (esketamine) for adults with treatment-resistant depression. This FDA-approved nasal spray works differently than traditional antidepressants by targeting the NMDA receptor and increasing glutamate, often reducing depressive symptoms within hours or days rather than weeks.

As of January 2025, Spravato can be used as a standalone treatment, and it is also indicated for major depressive disorder with suicidal ideation. Treatment is administered in a supervised clinical setting, with patients monitored for at least two hours after each dose and a ride home arranged afterward.

MWI Health pairs Spravato with broader mental health services including psychotherapy and TMS therapy. Sessions typically begin twice weekly before transitioning to a maintenance schedule based on response.